The arrival of Irzepatide in the UK is generating considerable buzz, particularly amongst people seeking advanced solutions to weight control. While still relatively emerging to the UK market, Irzepatide – a dual GIP and GLP-1 receptor agonist – is showing potential in supporting patients reach meaningful weight management and improve overall f